{"success":true,"data":{"pressRelease":{"id":"170347","rtpr_id":"nGNX2LvxHY-20261015","ticker":"PYPD","exchange":"NASDAQ","all_tickers":["PYPD"],"title":"PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026","author":"Globe Newswire","published_at":"2026-10-15T12:30:01.237Z","article_body":"Management to outline ‘PolyPid 2030’, the Company’s long-term vision and\npipeline strategy\n\nEvent to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized\nspecialist in lower extremity infectious diseases\n\nPetach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq:\nPYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical\ncompany dedicated to elevating treatment effectiveness, right where care\nbegins, today announced that it will host a virtual Investor Day on Wednesday,\nOctober 28, 2026, at 11:30 a.m. ET.\n\nDuring the event, PolyPid’s management team will outline the Company’s\n“PolyPid 2030” long-term growth and pipeline strategy. Management will\nalso provide an update on D-PLEX₁₀₀, the Company’s lead product\ncandidate for the prevention of colorectal surgical site infections, whose New\nDrug Application (“NDA”) is under U.S. Food and Drug Administration\n(“FDA”) Priority Review with a Prescription Drug User Fee Act\n(“PDUFA”) goal date of November 28, 2026, and will introduce PD01B, a new\nproduct candidate based on PolyPid’s Kynatrix™ delivery technology, being\ndeveloped for the treatment of diabetic foot infections.\n\nThe event will feature Key Opinion Leader (“KOL”) Warren S. Joseph, DPM,\nFIDSA, a leading podiatric physician and a specialist in the treatment of\nlower extremity infections, widely recognized as an authority on the diagnosis\nand treatment of diabetic foot infections, who will discuss the clinical\nburden of diabetic foot infections, the limitations of current treatment\napproaches, and the potential role of locally delivered, controlled-release\nantibiotic therapy in this setting. A live question-and-answer session with\nDr. Joseph and PolyPid’s management team will follow the formal\npresentations.\n\nInvestor Day Dial-In and Webcast Information:\n\nTo ensure you are connected prior to the beginning of the event, PolyPid\nsuggests registering a minimum of 5 minutes before the start of the event. For\nthose not planning to ask a question of the Company’s management or Dr.\nJoseph, the Company recommends listening via the webcast.\n\n Event:            PolyPid 2030: Virtual Investor Day and KOL Event                                    \n Date:             Wednesday, October 28, 2026                                                         \n Time:             11:30 a.m. Eastern Time                                                             \n Conference Call:  https://register-conf.media-server.com/register/BIb1af168335ad493c80fe51bb064f7b95  \n Webcast:          https://edge.media-server.com/mmc/p/97rvqcaj                                        \n\n \n\nThe presentation will be available on the Events & Presentations page of the\nInvestors section of the Company’s website at investors.polypid.com on the\nday of the event. A replay of the event will be available on the same page\nfollowing the event.\n\nAbout Warren S. Joseph, DPM, FIDSA\n\nDr. Warren S. Joseph is a specialist in the treatment of lower extremity\ninfectious diseases. He received his podiatric degree from the Dr. William M.\nScholl College of Podiatric Medicine in Chicago, Illinois. Dr. Joseph\ncompleted his postgraduate training in podiatric medicine and surgery at St.\nJoseph’s Hospital, and a fellowship in infectious diseases at Hahnemann\nUniversity School of Medicine, both in Philadelphia, Pennsylvania. He is\ncurrently an Adjunct Clinical Professor at the Arizona College of Podiatric\nMedicine at Midwestern University in Glendale, AZ.\n\nDr. Joseph is a fellow of the Infectious Diseases Society of America (IDSA)\nand is an author on the IDSA Diabetic Foot Infection Guidelines. He is also\ncertified by the American Board of Podiatric Medicine and currently serves as\nEditor-in-Chief of the Journal of the American Podiatric Medical Association.\nDr. Joseph lectures extensively and his presentations have focused on the\ntreatment of bacterial and fungal infections of the lower extremity. He has\nauthored over 100 publications in the field of lower extremity infections.\n\nAbout D-PLEX₁₀₀\nD-PLEX₁₀₀, PolyPid’s lead product candidate, is designed to provide\nlocal prolonged and controlled anti-bacterial activity directly at the\nsurgical site with the goal of preventing abdominal surgical site infections\n(“SSIs”). Following the administration of D-PLEX₁₀₀ into the\nsurgical site, PolyPid’s delivery technology, Kynatrix, is designed to pair\nwith Active Pharmaceutical Ingredients, enabling a prolonged and continuous\nrelease of the broad-spectrum antibiotic doxycycline, resulting in a high\nlocal concentration of the drug for a period of 30 days for the prevention of\nSSIs, with additional potential to prevent SSIs caused by antibiotic-resistant\nbacteria at the surgical site. In the Phase 3 SHIELD II trial, D-PLEX₁₀₀\nrecently demonstrated positive results in achieving its primary end point and\na 60% (p=0.0013) relative risk reduction at the secondary end point in SSI\nincidence following abdominal colorectal surgery with large incisions.\nD-PLEX₁₀₀ received Breakthrough Therapy Designation from the U.S. Food\nand Drug Administration for the prevention of SSIs in patients undergoing\nelective colorectal surgery.\n\nAbout PolyPid\nPolyPid Ltd. (Nasdaq: PYPD\n(https://www.globenewswire.com/Tracker?data=BxSoMocE-Va1WKwOUUt4WcGlvP69W2mTKQr4YhYUzTnjv4AEB5e5qHbdVOJE8wgxHmaEO-t_QzZG2-e0IKCP0Slk5y85vgAlvPd-jpdUNM-BLq7LQLhfADyIJPByD6Jz2S8J7XMw5zyCFnwfOgVprAd2zUQBWCN5eSpxRycUvd7Z4Hy8yCY27Kh3Ab5-u69gtr__n53h-fR4JQfjgMOII58XhedvB41aEC2_mTQDbiVMvh2j_YXAKSP0YWoSVyJ7w7r6MzS4Lc2-QZfs92xuCazHl0o8p3DspL_Xj8LeWhRJotx9H1HqUV0iZt03R90Aa7hJeISL3aO-XGR-_66L7bZ8bh5YZWAGztnEKIFb-SjO_GfAYsD5HTQCAm9qGClb2q-NqgUg7252l8WIUxKPP3Sh-tLCj7y-t0ufVdYI3FNi5_kqOjxNWw2_b4_WYF5ng7Mj9Frzm66EHGcTVxV4w2lv1z-4oxQI564cDi19ueen8JZJChlblNQzxM3EROA0cXg6WGJUlIdoVKLQ8MbD66bNmlRPdPq1BSM7u2vXZ7dfQdue1lCLqUbF_VdJ8v_yMl1_zIu7IEZBoHmRmyCaFF1c4XLwUMeZRwPxxJAj-nnFkngjPpuNhhQWADFlTQyU78bdQQ386gyB4tqD-osX2xCklNrayBWhhj4Mv4V0_tj9GdbGVMOWdRab_DDfLHF4e_81HmtwB1i5SIHLkXWK3xOYsF8g1khUn9nGEmrQPzRGeHO5a-GIO4PP976M6PMOVs7F7wJ_YUfWMfanQK5VcZABv6E9iZHBJ_SAn5LmQdoM9eWx8CJY6xEjeNjotVr-MyYFfrDPVdKrFQLnfxS-mjAJYqvTDW46d61xXQcsTQfgLplZei90dEzOhqaPvK1_wT9m9dJK0pthyy9e8RdpVVuSL2kiNDNALppmKlpcEEdvrus7OFx2fhIj-0cPIUns3wWjye8QyTCsgHKLI1k5fqgNWeN1ffHnPdAAfC9K9LRPs9OaHERHvoxKUrF2J4eEpsTWvifX7g2gevbRc8-sFWTW-8teUsZd2B1bzndOOdqKdF79EeowRYvSfqszxHTk9amv5k7ChfqFhZln1tjvGM8wcOvwNoB1BTl4PO8anYTPECQywXb4Qi5UM7fXkvOOXzGL7fSp5LmVEnOu-0aQryCBoAYqbw0PCVY-z41mw5VH4hVtbul4VF5EQ-414McE2OFNZLXgsYOO7QHQMJ1YrM5IbkymvWPN1IASSnMZZnPhtxlBcdHQv_iQ72g6hEli-TEHCEPlWZ0bt_FnLBzqozqPtYgxViXocSzvPHCSz3Oaig4ngO58W6HoKTqw93ax6q_yfC2bN0jca1WTJNuMZopb1tyPS_BB5BPfHIYFppqK7MigFYPIoaf7OqusgHDWGAW1Dw5TDWOdOmP2tNwYNH9r105wk7_3SscEt3qcBIJ_s-gr50dFgq6XaRF-gf_xYQ51ay7Xh3-s78ouswPKjSyg0-Z-zqERFSc-Mfn2FZEUl_QvKh1G1ziluM7P81-c1fQkqKEFW52CRUCPmtC3Ewfml5UAko1G58hxL0dOwI74xeuu3mUxctMrm-rubnlBniSWg8wjSPeQip9FI53sjdAqTsal20cOhcwIMHvHTErbif1jxcTUNqR0H5O83JZwtiUazELW30J51FqhZp-KbY4bSzSaCaeXffvca8aYNCIFyvAXXBAQ3JkP8SVEYdKmax7ITRAzCLVHK7oCkVErYkQ5aGQ72DAzDSbMNFlwSWXVI4aQ1VDIIdBvOV9OP4A22SSC910r9uwGkB5nO3OGkkO0sF4FSntP2ROy5VSr2t-kUFKUJhLPeXJL9K9rZRFTb7zL5rl3TTGNiRgkXzBOWugEnAO2xssSg23cL8v7TuWAK6SnULg4rc4O-DCr1BUqkY8SPjBkAMEObW3h9e87VuqC5w87pqN0hxc7TLyUitrV_59hEdp5QGTriwwAmFOOzi3PdNL8ggRiyDhnBKtPlNV7W7AyXhpB-v3C8S98cP2dpd5RTK9EuxwhUcGg08Np8Ymj5J2Wb3eTOlj4DFcgnn61NoOYiEIgfRtSUJLF5Mg8LlCdOARlITYQZk6vGgRsBvY-p3_sP9rF7mh4oec8C6wE7KGYiU6Z3dVLPiCz3cG0eskrTrowt0eqp56EkGt9vnnkkc4aLBvxwMT_9hNqHWr8-a2crnYmwsw0sdEpI-wblpJkmwC0tum6XR62EmBAwXiOZMOWfKnHZUOoyPVobDcFg9BdgDuHg8n48ZYTu84=))\nis an innovative biopharmaceutical company dedicated to elevating treatment\neffectiveness, right where care begins. The Company develops long-acting,\ncontrolled-release drugs designed to deliver therapy precisely at the site of\ncare, addressing critical unmet medical needs across a wide and diverse\npipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s\nlead product, D-PLEX₁₀₀, successfully met its primary and all key\nsecondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention\nof surgical site infections. Guided by a commitment to precision and\ninnovation, PolyPid is redefining how therapies perform and raise the standard\nof patient care. For additional Company information, please visit\nhttp://www.polypid.com and follow us on Twitter (X)\n(https://www.globenewswire.com/Tracker?data=t4VY5bvO-B3TH190EmXJo0jRuTH7mWO5stcXal15klJo8lABkNNFkgLFNpVuC7mWEac7vt6pHTOSAboegCMnniRYdrM54M0HuIHNTE3wfcSN35zuCpcQbqOm6D_b7Jseh6Ol1tQcvxwxBp4Ga7ETNOrwi-MoCJGZXjSETT4waXqVFKGxtKkL2RQTVf38OAGCtzfNnZqGYynd5cQOL4gT4bXYbIMmWGHD8nHB3LmxIVbyPmqAQquXYMMO-mUegxr-0DZyA7u3RUTr1S_eFJZgpEyLO9V3kPFcE6-7H1U8EjFygzwb2_gKplxM36bHKatIY1XjHK39JcnlpE9-KuhTETgnAS9FN3ZZDaiHreyXo8mG7x5sprAbITS2eV1U2WEi2qPPYDoQgl2ywXbx9XRoJtss8DJ3pcg42oecpc8IapIC4fyQl2wKb0mHb7aVTT9ZCldNSMysW5nWYBQMYMSyK3oFzGT6h3-Tk2IFZ_-YDWi7FkyvNX9Cu2z0UsXWk0W_H3l_NcHCi3tjvMh-qVeRybQGT3oK19Qa6mpOjkrpYVrU6xrcuyi3riKPeTyjnmXSdr5RjqRLCIJDxtcM4lVnBHMTI3ahoskgzcDIj5L2x08nnGa2OP3POxEcKleaEsPO4fkK-r68d_wzf4tVe-1j6wp6PXGdF75G0rmXnyy8h2o=)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=nu1CJE3M8Y-F3Kr5ZnMIGZJYzgsc9SGFlH4SxRm4FXbkVdQSder8T-OvBUNtlY7cx2wJdeV-l0RvfP5ECMwxS0RDN_1FEZbFRansDdZ1afLjJXP04Dw53xd95g9oikLfb5j6G091VQWjKMMcGmydj-9t5VwyK56RWINfqXSdgM2-gWjy1yLSjqtExzZUukEPOkFJbCUpnCf6ZJsgRedjh3EL4sOJltxoFZ4Q8FXPXbYZMCCBBDDWuTN9Qk_YfzXOziMNxMRuYl8TEcug2m95GcY6Ez0-Lq_AKJ5vrr7WzuQM2rTwjolT1PBPAUZ8zJMlqGUZsq3oQG0_5EOG0yxsVlU9bawpCyk_xYBJoXrK-T5FKbBKhk5NlG2jxlNssEY3f-i83UsvZ4NXVgoWrU3qOvRp9IF_2P0hnbpFoX7DEUBg2EEhez7B-rMuY77h8Ybs3UbACyRGwVZevjAnHEsqQmB5J7Je5WwSyXscqNUPDeIWD6VlrzA2a98g0SAriVy_GKIN6pwleZX9TbUBKqTsodlIKi0MdiPKTSxlbZs2pcESU52C2K4yt8AqcfbnOUxK_hb6ncRgee4nYhsvQhbhQlYZcd4aDZGeZEuktgLS6AyCdrlJp6NrqmPK_VrrxaBWZ148Z-4Jd8_QmCPl3FlftOvfQ74yh-h4Rkrq6L9WNJW5dzO5NYkIPgthALvpMJe7).\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act and other securities\nlaws. Words such as “expects,” “anticipates,” “intends,”\n“plans,” “believes,” “seeks,” “estimates” and similar\nexpressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the Company’s long-term vision, long-term\ngrowth and pipeline strategy, the planned introduction and development of\nPD01B and its potential role in the treatment of diabetic foot infections, the\npotential role of locally delivered, controlled-release antibiotic therapy,\nthe PDUFA goal date and the potential FDA approval of D-PLEX₁₀₀.\nForward-looking statements are not historical facts, and are based upon\nmanagement’s current expectations, beliefs and projections, many of which,\nby their nature, are inherently uncertain. Such expectations, beliefs and\nprojections are expressed in good faith. However, there can be no assurance\nthat management’s expectations, beliefs and projections will be achieved,\nand actual results may differ materially from what is expressed in or\nindicated by the forward-looking statements. Forward-looking statements are\nsubject to risks and uncertainties that could cause actual performance or\nresults to differ materially from those expressed in the forward-looking\nstatements. For a more detailed description of the risks and uncertainties\naffecting the Company, reference is made to the Company’s reports filed from\ntime to time with the Securities and Exchange Commission, including, but not\nlimited to, the risks detailed in the Company’s Annual Report on Form 20-F\nfiled on February 25, 2026. Forward-looking statements speak only as of the\ndate the statements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. PolyPid is not responsible\nfor the contents of third-party websites.\n\nCompany Contact:\nPolyPid Ltd.\nOri Warshavsky\n908-858-5995\nIR@Polypid.com\n\nInvestor Relations Contact:\nArx Investor Relations\nNorth American Equities Desk\npolypid@arxhq.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/202fc254-aac1-49c2-a08d-cc0efc938460)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2LvxHY-20261015","title":"PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026","author":"Globe Newswire","ticker":"PYPD","created":"2026-10-15T12:30:01.237Z","tickers":["PYPD"],"exchange":"NASDAQ","article_body":"Management to outline ‘PolyPid 2030’, the Company’s long-term vision and\npipeline strategy\n\nEvent to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized\nspecialist in lower extremity infectious diseases\n\nPetach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq:\nPYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical\ncompany dedicated to elevating treatment effectiveness, right where care\nbegins, today announced that it will host a virtual Investor Day on Wednesday,\nOctober 28, 2026, at 11:30 a.m. ET.\n\nDuring the event, PolyPid’s management team will outline the Company’s\n“PolyPid 2030” long-term growth and pipeline strategy. Management will\nalso provide an update on D-PLEX₁₀₀, the Company’s lead product\ncandidate for the prevention of colorectal surgical site infections, whose New\nDrug Application (“NDA”) is under U.S. Food and Drug Administration\n(“FDA”) Priority Review with a Prescription Drug User Fee Act\n(“PDUFA”) goal date of November 28, 2026, and will introduce PD01B, a new\nproduct candidate based on PolyPid’s Kynatrix™ delivery technology, being\ndeveloped for the treatment of diabetic foot infections.\n\nThe event will feature Key Opinion Leader (“KOL”) Warren S. Joseph, DPM,\nFIDSA, a leading podiatric physician and a specialist in the treatment of\nlower extremity infections, widely recognized as an authority on the diagnosis\nand treatment of diabetic foot infections, who will discuss the clinical\nburden of diabetic foot infections, the limitations of current treatment\napproaches, and the potential role of locally delivered, controlled-release\nantibiotic therapy in this setting. A live question-and-answer session with\nDr. Joseph and PolyPid’s management team will follow the formal\npresentations.\n\nInvestor Day Dial-In and Webcast Information:\n\nTo ensure you are connected prior to the beginning of the event, PolyPid\nsuggests registering a minimum of 5 minutes before the start of the event. For\nthose not planning to ask a question of the Company’s management or Dr.\nJoseph, the Company recommends listening via the webcast.\n\n Event:            PolyPid 2030: Virtual Investor Day and KOL Event                                    \n Date:             Wednesday, October 28, 2026                                                         \n Time:             11:30 a.m. Eastern Time                                                             \n Conference Call:  https://register-conf.media-server.com/register/BIb1af168335ad493c80fe51bb064f7b95  \n Webcast:          https://edge.media-server.com/mmc/p/97rvqcaj                                        \n\n \n\nThe presentation will be available on the Events & Presentations page of the\nInvestors section of the Company’s website at investors.polypid.com on the\nday of the event. A replay of the event will be available on the same page\nfollowing the event.\n\nAbout Warren S. Joseph, DPM, FIDSA\n\nDr. Warren S. Joseph is a specialist in the treatment of lower extremity\ninfectious diseases. He received his podiatric degree from the Dr. William M.\nScholl College of Podiatric Medicine in Chicago, Illinois. Dr. Joseph\ncompleted his postgraduate training in podiatric medicine and surgery at St.\nJoseph’s Hospital, and a fellowship in infectious diseases at Hahnemann\nUniversity School of Medicine, both in Philadelphia, Pennsylvania. He is\ncurrently an Adjunct Clinical Professor at the Arizona College of Podiatric\nMedicine at Midwestern University in Glendale, AZ.\n\nDr. Joseph is a fellow of the Infectious Diseases Society of America (IDSA)\nand is an author on the IDSA Diabetic Foot Infection Guidelines. He is also\ncertified by the American Board of Podiatric Medicine and currently serves as\nEditor-in-Chief of the Journal of the American Podiatric Medical Association.\nDr. Joseph lectures extensively and his presentations have focused on the\ntreatment of bacterial and fungal infections of the lower extremity. He has\nauthored over 100 publications in the field of lower extremity infections.\n\nAbout D-PLEX₁₀₀\nD-PLEX₁₀₀, PolyPid’s lead product candidate, is designed to provide\nlocal prolonged and controlled anti-bacterial activity directly at the\nsurgical site with the goal of preventing abdominal surgical site infections\n(“SSIs”). Following the administration of D-PLEX₁₀₀ into the\nsurgical site, PolyPid’s delivery technology, Kynatrix, is designed to pair\nwith Active Pharmaceutical Ingredients, enabling a prolonged and continuous\nrelease of the broad-spectrum antibiotic doxycycline, resulting in a high\nlocal concentration of the drug for a period of 30 days for the prevention of\nSSIs, with additional potential to prevent SSIs caused by antibiotic-resistant\nbacteria at the surgical site. In the Phase 3 SHIELD II trial, D-PLEX₁₀₀\nrecently demonstrated positive results in achieving its primary end point and\na 60% (p=0.0013) relative risk reduction at the secondary end point in SSI\nincidence following abdominal colorectal surgery with large incisions.\nD-PLEX₁₀₀ received Breakthrough Therapy Designation from the U.S. Food\nand Drug Administration for the prevention of SSIs in patients undergoing\nelective colorectal surgery.\n\nAbout PolyPid\nPolyPid Ltd. (Nasdaq: PYPD\n(https://www.globenewswire.com/Tracker?data=BxSoMocE-Va1WKwOUUt4WcGlvP69W2mTKQr4YhYUzTnjv4AEB5e5qHbdVOJE8wgxHmaEO-t_QzZG2-e0IKCP0Slk5y85vgAlvPd-jpdUNM-BLq7LQLhfADyIJPByD6Jz2S8J7XMw5zyCFnwfOgVprAd2zUQBWCN5eSpxRycUvd7Z4Hy8yCY27Kh3Ab5-u69gtr__n53h-fR4JQfjgMOII58XhedvB41aEC2_mTQDbiVMvh2j_YXAKSP0YWoSVyJ7w7r6MzS4Lc2-QZfs92xuCazHl0o8p3DspL_Xj8LeWhRJotx9H1HqUV0iZt03R90Aa7hJeISL3aO-XGR-_66L7bZ8bh5YZWAGztnEKIFb-SjO_GfAYsD5HTQCAm9qGClb2q-NqgUg7252l8WIUxKPP3Sh-tLCj7y-t0ufVdYI3FNi5_kqOjxNWw2_b4_WYF5ng7Mj9Frzm66EHGcTVxV4w2lv1z-4oxQI564cDi19ueen8JZJChlblNQzxM3EROA0cXg6WGJUlIdoVKLQ8MbD66bNmlRPdPq1BSM7u2vXZ7dfQdue1lCLqUbF_VdJ8v_yMl1_zIu7IEZBoHmRmyCaFF1c4XLwUMeZRwPxxJAj-nnFkngjPpuNhhQWADFlTQyU78bdQQ386gyB4tqD-osX2xCklNrayBWhhj4Mv4V0_tj9GdbGVMOWdRab_DDfLHF4e_81HmtwB1i5SIHLkXWK3xOYsF8g1khUn9nGEmrQPzRGeHO5a-GIO4PP976M6PMOVs7F7wJ_YUfWMfanQK5VcZABv6E9iZHBJ_SAn5LmQdoM9eWx8CJY6xEjeNjotVr-MyYFfrDPVdKrFQLnfxS-mjAJYqvTDW46d61xXQcsTQfgLplZei90dEzOhqaPvK1_wT9m9dJK0pthyy9e8RdpVVuSL2kiNDNALppmKlpcEEdvrus7OFx2fhIj-0cPIUns3wWjye8QyTCsgHKLI1k5fqgNWeN1ffHnPdAAfC9K9LRPs9OaHERHvoxKUrF2J4eEpsTWvifX7g2gevbRc8-sFWTW-8teUsZd2B1bzndOOdqKdF79EeowRYvSfqszxHTk9amv5k7ChfqFhZln1tjvGM8wcOvwNoB1BTl4PO8anYTPECQywXb4Qi5UM7fXkvOOXzGL7fSp5LmVEnOu-0aQryCBoAYqbw0PCVY-z41mw5VH4hVtbul4VF5EQ-414McE2OFNZLXgsYOO7QHQMJ1YrM5IbkymvWPN1IASSnMZZnPhtxlBcdHQv_iQ72g6hEli-TEHCEPlWZ0bt_FnLBzqozqPtYgxViXocSzvPHCSz3Oaig4ngO58W6HoKTqw93ax6q_yfC2bN0jca1WTJNuMZopb1tyPS_BB5BPfHIYFppqK7MigFYPIoaf7OqusgHDWGAW1Dw5TDWOdOmP2tNwYNH9r105wk7_3SscEt3qcBIJ_s-gr50dFgq6XaRF-gf_xYQ51ay7Xh3-s78ouswPKjSyg0-Z-zqERFSc-Mfn2FZEUl_QvKh1G1ziluM7P81-c1fQkqKEFW52CRUCPmtC3Ewfml5UAko1G58hxL0dOwI74xeuu3mUxctMrm-rubnlBniSWg8wjSPeQip9FI53sjdAqTsal20cOhcwIMHvHTErbif1jxcTUNqR0H5O83JZwtiUazELW30J51FqhZp-KbY4bSzSaCaeXffvca8aYNCIFyvAXXBAQ3JkP8SVEYdKmax7ITRAzCLVHK7oCkVErYkQ5aGQ72DAzDSbMNFlwSWXVI4aQ1VDIIdBvOV9OP4A22SSC910r9uwGkB5nO3OGkkO0sF4FSntP2ROy5VSr2t-kUFKUJhLPeXJL9K9rZRFTb7zL5rl3TTGNiRgkXzBOWugEnAO2xssSg23cL8v7TuWAK6SnULg4rc4O-DCr1BUqkY8SPjBkAMEObW3h9e87VuqC5w87pqN0hxc7TLyUitrV_59hEdp5QGTriwwAmFOOzi3PdNL8ggRiyDhnBKtPlNV7W7AyXhpB-v3C8S98cP2dpd5RTK9EuxwhUcGg08Np8Ymj5J2Wb3eTOlj4DFcgnn61NoOYiEIgfRtSUJLF5Mg8LlCdOARlITYQZk6vGgRsBvY-p3_sP9rF7mh4oec8C6wE7KGYiU6Z3dVLPiCz3cG0eskrTrowt0eqp56EkGt9vnnkkc4aLBvxwMT_9hNqHWr8-a2crnYmwsw0sdEpI-wblpJkmwC0tum6XR62EmBAwXiOZMOWfKnHZUOoyPVobDcFg9BdgDuHg8n48ZYTu84=))\nis an innovative biopharmaceutical company dedicated to elevating treatment\neffectiveness, right where care begins. The Company develops long-acting,\ncontrolled-release drugs designed to deliver therapy precisely at the site of\ncare, addressing critical unmet medical needs across a wide and diverse\npipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s\nlead product, D-PLEX₁₀₀, successfully met its primary and all key\nsecondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention\nof surgical site infections. Guided by a commitment to precision and\ninnovation, PolyPid is redefining how therapies perform and raise the standard\nof patient care. For additional Company information, please visit\nhttp://www.polypid.com and follow us on Twitter (X)\n(https://www.globenewswire.com/Tracker?data=t4VY5bvO-B3TH190EmXJo0jRuTH7mWO5stcXal15klJo8lABkNNFkgLFNpVuC7mWEac7vt6pHTOSAboegCMnniRYdrM54M0HuIHNTE3wfcSN35zuCpcQbqOm6D_b7Jseh6Ol1tQcvxwxBp4Ga7ETNOrwi-MoCJGZXjSETT4waXqVFKGxtKkL2RQTVf38OAGCtzfNnZqGYynd5cQOL4gT4bXYbIMmWGHD8nHB3LmxIVbyPmqAQquXYMMO-mUegxr-0DZyA7u3RUTr1S_eFJZgpEyLO9V3kPFcE6-7H1U8EjFygzwb2_gKplxM36bHKatIY1XjHK39JcnlpE9-KuhTETgnAS9FN3ZZDaiHreyXo8mG7x5sprAbITS2eV1U2WEi2qPPYDoQgl2ywXbx9XRoJtss8DJ3pcg42oecpc8IapIC4fyQl2wKb0mHb7aVTT9ZCldNSMysW5nWYBQMYMSyK3oFzGT6h3-Tk2IFZ_-YDWi7FkyvNX9Cu2z0UsXWk0W_H3l_NcHCi3tjvMh-qVeRybQGT3oK19Qa6mpOjkrpYVrU6xrcuyi3riKPeTyjnmXSdr5RjqRLCIJDxtcM4lVnBHMTI3ahoskgzcDIj5L2x08nnGa2OP3POxEcKleaEsPO4fkK-r68d_wzf4tVe-1j6wp6PXGdF75G0rmXnyy8h2o=)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=nu1CJE3M8Y-F3Kr5ZnMIGZJYzgsc9SGFlH4SxRm4FXbkVdQSder8T-OvBUNtlY7cx2wJdeV-l0RvfP5ECMwxS0RDN_1FEZbFRansDdZ1afLjJXP04Dw53xd95g9oikLfb5j6G091VQWjKMMcGmydj-9t5VwyK56RWINfqXSdgM2-gWjy1yLSjqtExzZUukEPOkFJbCUpnCf6ZJsgRedjh3EL4sOJltxoFZ4Q8FXPXbYZMCCBBDDWuTN9Qk_YfzXOziMNxMRuYl8TEcug2m95GcY6Ez0-Lq_AKJ5vrr7WzuQM2rTwjolT1PBPAUZ8zJMlqGUZsq3oQG0_5EOG0yxsVlU9bawpCyk_xYBJoXrK-T5FKbBKhk5NlG2jxlNssEY3f-i83UsvZ4NXVgoWrU3qOvRp9IF_2P0hnbpFoX7DEUBg2EEhez7B-rMuY77h8Ybs3UbACyRGwVZevjAnHEsqQmB5J7Je5WwSyXscqNUPDeIWD6VlrzA2a98g0SAriVy_GKIN6pwleZX9TbUBKqTsodlIKi0MdiPKTSxlbZs2pcESU52C2K4yt8AqcfbnOUxK_hb6ncRgee4nYhsvQhbhQlYZcd4aDZGeZEuktgLS6AyCdrlJp6NrqmPK_VrrxaBWZ148Z-4Jd8_QmCPl3FlftOvfQ74yh-h4Rkrq6L9WNJW5dzO5NYkIPgthALvpMJe7).\n\nForward-Looking Statements\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act and other securities\nlaws. Words such as “expects,” “anticipates,” “intends,”\n“plans,” “believes,” “seeks,” “estimates” and similar\nexpressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the Company’s long-term vision, long-term\ngrowth and pipeline strategy, the planned introduction and development of\nPD01B and its potential role in the treatment of diabetic foot infections, the\npotential role of locally delivered, controlled-release antibiotic therapy,\nthe PDUFA goal date and the potential FDA approval of D-PLEX₁₀₀.\nForward-looking statements are not historical facts, and are based upon\nmanagement’s current expectations, beliefs and projections, many of which,\nby their nature, are inherently uncertain. Such expectations, beliefs and\nprojections are expressed in good faith. However, there can be no assurance\nthat management’s expectations, beliefs and projections will be achieved,\nand actual results may differ materially from what is expressed in or\nindicated by the forward-looking statements. Forward-looking statements are\nsubject to risks and uncertainties that could cause actual performance or\nresults to differ materially from those expressed in the forward-looking\nstatements. For a more detailed description of the risks and uncertainties\naffecting the Company, reference is made to the Company’s reports filed from\ntime to time with the Securities and Exchange Commission, including, but not\nlimited to, the risks detailed in the Company’s Annual Report on Form 20-F\nfiled on February 25, 2026. Forward-looking statements speak only as of the\ndate the statements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. PolyPid is not responsible\nfor the contents of third-party websites.\n\nCompany Contact:\nPolyPid Ltd.\nOri Warshavsky\n908-858-5995\nIR@Polypid.com\n\nInvestor Relations Contact:\nArx Investor Relations\nNorth American Equities Desk\npolypid@arxhq.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/202fc254-aac1-49c2-a08d-cc0efc938460)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T12:30:01.679952818Z","server_sent_at_ms":1792067401679},"received_at":"2026-10-15T12:30:01.730Z","source_url":null},"analysis":{"id":"158537","press_release_id":"170347","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"PolyPid will host a virtual Investor Day on October 28, 2026, at 11:30 a.m. ET, where management will outline its 'PolyPid 2030' long-term growth and pipeline strategy.\n\nThe event will include an update on lead candidate D-PLEX100, whose NDA is under FDA Priority Review with a PDUFA goal date of November 28, 2026, and will introduce PD01B, a new candidate for diabetic foot infections based on the Kynatrix delivery technology.\n\nKOL Dr. Warren S. Joseph, an authority on diabetic foot infections, will discuss the clinical burden of the condition and the potential role of locally delivered controlled-release antibiotic therapy.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar note: PYPD investor day on Oct 28 ahead of the Nov 28 PDUFA date for D-PLEX100; PD01B pipeline introduction could be the incremental news."},"keyFigures":{"customDimensions":{"event_date":"October 28, 2026","pdufa_goal_date":"November 28, 2026","shield_ii_relative_risk_reduction":"60%"}},"quotedText":"a 60% (p=0.0013) relative risk reduction at the secondary end point in SSI incidence following abdominal colorectal surgery with large incisions","namedEntities":{"people":[{"name":"Warren S. Joseph, DPM, FIDSA","role":"Key Opinion Leader, specialist in lower extremity infectious diseases"},{"name":"Ori Warshavsky","role":"Company contact"}],"products":["D-PLEX₁₀₀","PD01B","Kynatrix"],"companies":[{"name":"PolyPid Ltd.","ticker":"PYPD","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a scheduling notice for a virtual investor day, not new results or a regulatory decision. The only substantive content is boilerplate background on D-PLEX100's already-disclosed Phase 3 data and PDUFA date, plus an introduction of a new pipeline candidate."},"tickerRelevance":{"others":[],"primary":"PYPD"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"investor-day-scheduling-notice","issuerAuthored":true,"pdufaProximity":"PDUFA within ~6 weeks may amplify interest in the event"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"PolyPid will host a virtual Investor Day on October 28, 2026, at 11:30 a.m. ET, where management will outline its 'PolyPid 2030' long-term growth and pipeline strategy.\n\nThe event will include an update on lead candidate D-PLEX100, whose NDA is under FDA Priority Review with a PDUFA goal date of November 28, 2026, and will introduce PD01B, a new candidate for diabetic foot infections based on the Kynatrix delivery technology.\n\nKOL Dr. Warren S. Joseph, an authority on diabetic foot infections, will discuss the clinical burden of the condition and the potential role of locally delivered controlled-release antibiotic therapy.","key_figures":{"customDimensions":{"event_date":"October 28, 2026","pdufa_goal_date":"November 28, 2026","shield_ii_relative_risk_reduction":"60%"}},"named_entities":{"people":[{"name":"Warren S. Joseph, DPM, FIDSA","role":"Key Opinion Leader, specialist in lower extremity infectious diseases"},{"name":"Ori Warshavsky","role":"Company contact"}],"products":["D-PLEX₁₀₀","PD01B","Kynatrix"],"companies":[{"name":"PolyPid Ltd.","ticker":"PYPD","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T12:30:20.085Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"investor-day-scheduling-notice","issuerAuthored":true,"pdufaProximity":"PDUFA within ~6 weeks may amplify interest in the event"}},"durationMs":5146,"modelName":"glm-5.3-flashx"}}